% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Werner:864920,
      author       = {Werner, J. M. and Stoffels, G. and Lichtenstein, T. and
                      Borggrefe, J. and Lohmann, P. and Ceccon, G. and Shah, N. J.
                      and Fink, G. R. and Langen, K. J. and Kabbasch, C. and
                      Galldiks, N.},
      title        = {{D}ifferentiation of treatment-related changes from tumor
                      progression: {A} direct comparison between dynamic {FET}
                      {PET} and {ADC} values obtained from {DWI} {MRI}},
      reportid     = {FZJ-2019-04523},
      year         = {2019},
      abstract     = {V29Differentiation of treatment-related changes from
                      high-grade glioma progression: A direct comparison between
                      FET PET and ADC values obtained by DWI MRIJ. Werner1, G.
                      Stoffels2, T. Lichtenstein3, J. Borggrefe3, G. Ceccon1, N.
                      J. Shah2, G. R. Fink1, K. J. Langen2, C. Kabbasch3, N.
                      Galldiks11University Hospital Cologne, Dept. of Neurology,
                      Cologne; 2Research Center Jülich, Inst. of Neuroscience and
                      Medicine (INM-4), Jülich; 3University Hospital Cologne,
                      Dept. of Neuroradiology, CologneZiel/Aim:Following brain
                      cancer treatment, the capacity of anatomical MRI to
                      differentiate neoplastic tissue from treatment-related
                      changes such as pseudoprogression is limited. The aim of
                      this study was to compare apparent diffusion coefficient
                      (ADC) values obtained by diffusion-weighted MRI (DWI) with
                      static parameters of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
                      PET for the differentiation of treatment-related changes
                      from tumor progression.Methodik/Methods:Forty-eight
                      pretreated high-grade glioma patients (mean age, 50±15
                      years) with anatomical MRI findings suspicious for tumor
                      progression (median time after completion of last treatment,
                      16 weeks) were additionally investigated using DWI MRI and
                      FET PET. Maximum and mean tumor-to-brain ratios
                      (TBRmax/mean) of FET uptake were determined (20-40 minutes
                      post-injection). Regions-of-Interest analyses were performed
                      concerning the enhancing lesion on ADC maps calculated from
                      DWI MRI. Diagnoses were confirmed neuropathologically
                      $(21\%;$ 10 patients) or clinico-radiologically $(79\%;$ 38
                      patients). Diagnostic performances of TBRs and ADC values
                      for the correct differentiation were evaluated each alone
                      using receiver-operating-characteristic analyses, or the
                      Fisher Exact test for a combinational
                      approach.Ergebnisse/Results:Ten of 48 patients had
                      treatment-related changes $(21\%).$ The diagnostic
                      performance of FET PET was clearly higher (threshold
                      TBRmean, 1.95; sensitivity, $100\%;$ specificity, $79\%;$
                      accuracy, $83\%;$ AUC 0.89±0.05; P-3 mm2/s; sensitivity,
                      $60\%;$ specificity; $79\%;$ accuracy, $75\%;$ AUC
                      0.73±0.09; P=0.05). The combination of both imaging
                      parameters did not increase the accuracy $(64\%;$
                      P=0.144).Schlussfolgerungen/Conclusions:Static FET PET seems
                      to add valuable clinical information regarding the
                      differentiation of early treatment-related changes from
                      tumor progression and outperforms ADC values for this highly
                      relevant clinical question.},
      month         = {Apr},
      date          = {2019-04-03},
      organization  = {Jahrestagung der Deutschen
                       Gesellschaft für Nuklearmedizin 2019,
                       Bremen (Germany), 3 Apr 2019 - 6 Apr
                       2019},
      cin          = {INM-3 / INM-4},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)1},
      url          = {https://juser.fz-juelich.de/record/864920},
}